WeTrials
Active, not recruiting

SPOTLIGHT 204: A Multicenter, Phase 2b, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High Risk Basal Cell Carcinoma

What is this study?

This study is testing an experimental medication called BO-112 to see how well it works and if it is safe for treating a common type of skin cancer called basal cell carcinoma. Researchers want to see if injecting the medication directly into the skin cancer before surgery can help treat the tumor.

Who can participate?

You may be able to join if you are 18 or older and have a type of skin cancer that can be surgically removed. Participants also need to meet specific health and lab requirements, and cannot have certain conditions like Gorlin's syndrome or recent radiation on the cancer spot.

What will happen?

During the study, you will receive injections of the study drug directly into your skin cancer spots before your scheduled surgery. Doctors will closely monitor your safety, check your skin visually, and examine the removed tissue after surgery to see how well the treatment worked.

Where and when?

This study is currently active and takes place at medical centers in Beersheba, Haifa, and Jerusalem, Israel. Although it is active, it is not currently looking for new participants.

Key Points
  • 1Testing an experimental injection called BO-112 for common skin cancer
  • 2Involves receiving treatment directly into the cancer spot before surgery
  • 3Study is active in multiple locations in Israel but not currently recruiting

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Basal Cell Carcinoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.